Fig. 2. Phenotypic analysis of primary human pDCs treated with native or
oxidatively modified mtDNA. Freshly isolated primary human pDCs were exposed
to native or oxidatively modified mtDNA extracted from untreated or antimycin
A-exposed HL-60 cells. In parallel experiments pDCs were preincubated for 1 h
with specific TLR9 antagonist (TTAGGG) and then treated with native or oxidized
mtDNA. Following a 24-h activation, expression of CD86 (A), HLA-DQ (B), and CD83
(C) was determined by flow cytometry. Relative fluorescence was calculated using the
respective isotype-matched control for each monoclonal antibody. Data are presented
as means 7 SE of three independent experiments. ** Po0.01, **** Po0.0001 vs
untreated cells; ## Po0.01, #### Po0.0001 vs mtDNA- or ox-mtDNA-treated cells.
Ox-mtDNA: oxidatively modified mtDNA.